Senseonics Q1 2025: Key Contradictions in Reimbursement, International Growth, and Strategic Partnerships

Reimbursement and Medicare transition, international revenue growth and OUS launch strategy, Ascensia's role in the 365-day sensor launch, and integration work for Twiist are the key contradictions discussed in Senseonics' latest 2025Q1 earnings call.



Revenue Growth and CGM Integration:
- Senseonics reported net revenue of $6.3 million for Q1 2025, up 24% year-on-year.
- Growth was driven by the integration of the Eversense 365 continuous glucose monitor with the twiist automated insulin delivery system, as well as increased adoption of the Eversense 365.

CE Mark Application and European Launch:
- Senseonics filed a CE Mark application for the Eversense 365 in Q1 2025, with a planned European launch in the second half of the year.
- The European launch is expected to provide meaningful global supply chain synergies and cost of goods improvements.

Payer Reimbursement and Medicare Update:
- The company continued progress in transitioning U.S. reimbursement for Eversense from 180 to 365 days, including a positive update on Medicare reimbursement.
- The 2025 physician fee schedule updated payment for a full year of Eversense, retroactive to January 1, which is anticipated to drive more patient and provider adoption.

Partnership and Collaboration:
- Senseonics announced its first AID integration of Eversense 365 with the twiist automated insulin delivery system by Sequel, expected to launch in Q3 2025.
- This collaboration is seen as a significant step forward for both companies in improving personalization and health outcomes for diabetes patients.

Financial Performance and Cost Management:
- Net loss decreased by $4.6 million year-on-year, primarily due to improved gross profit margins of Eversense 365 and reduced research and development costs.
- The company reported a cash runway extension to mid-2026, following the receipt of approximately $27 million from the sale of common stock.